Group 1 - The core viewpoint of the news is the performance and financial details of Shenzhen Meihao Medical Technology Co., Ltd., which saw a stock price increase of 5.89% to 26.23 CNY per share, with a total market capitalization of 14.921 billion CNY [1] - The company was established on July 15, 2010, and went public on October 12, 2022, focusing on the design, development, manufacturing, and sales of medical device components and products [1] - The revenue composition of the company includes: home respiratory machine components (59.48%), home and consumer electronics components (14.61%), other medical product components (10.33%), cochlear implant components (8.16%), precision molds and automation equipment (5.63%), other categories (1.09%), and proprietary products (0.70%) [1] Group 2 - From the perspective of fund holdings, Meihao Medical is a significant investment for the China Europe Fund, specifically in the China Europe Jiaxuan Mixed A Fund (010947), which held 823,900 shares, accounting for 1.53% of the fund's net value [2] - The fund has achieved a year-to-date return of 27.32% and a one-year return of 58.99%, ranking 2505 out of 8177 and 1917 out of 7982 respectively in its category [2] - The fund manager, Wang Jian, has a tenure of 15 years and 322 days, with the fund's total asset size at 6.565 billion CNY and a best return of 200.87% during his management [3]
美好医疗股价涨5.89%，中欧基金旗下1只基金重仓，持有82.39万股浮盈赚取120.29万元